UCSF Benioff Children's Hospital
Welcome,         Profile    Billing    Logout  
 24 Trials 
64 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Walters, Mark
GRASP, NCT05353647: A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (, BMT CTN 2001)

Active, not recruiting
2
25
US
Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
David Williams, National Heart, Lung, and Blood Institute (NHLBI), California Institute for Regenerative Medicine (CIRM), bluebird bio, Blood and Marrow Transplant Clinical Trials Network
Sickle Cell Disease
05/26
05/26
NCT04774536: Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease

Recruiting
1/2
9
US
CRISPR_SCD001
Mark Walters, MD, University of California, Los Angeles, University of California, Berkeley
Sickle Cell Disease
03/27
03/29
NCT02843347: STRIDE Biorepository

Recruiting
N/A
200
US
Blood draw
Emory University, National Heart, Lung, and Blood Institute (NHLBI)
Anemia, Sickle Cell
07/23
07/23
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
Kohn, Donald B
RP-L201-0318, NCT03812263 / 2020-000517-33: A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I

Completed
1/2
9
Europe, US
RP-L201
Rocket Pharmaceuticals Inc., California Institute for Regenerative Medicine (CIRM)
Leukocyte Adhesion Defect - Type I
09/23
09/23
NCT02234934: Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease

Completed
1/2
10
US
Lentiviral G1XCGD Gene Therapy, G1XCGD (pCCLChimGp91/VSVg lentiviral vector)
University of California, Los Angeles, Boston Children's Hospital, National Heart, Lung, and Blood Institute (NHLBI), Genethon, California Institute for Regenerative Medicine (CIRM)
Granulomatous Disease, Chronic, X-linked
09/24
12/24
NCT04774536: Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease

Recruiting
1/2
9
US
CRISPR_SCD001
Mark Walters, MD, University of California, Los Angeles, University of California, Berkeley
Sickle Cell Disease
03/27
03/29
NCT03311503: Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 with Low Dose Targeted Busulfan Conditioning

Recruiting
1/2
12
US
autologous CD34+ cell transduced with G2SCID vector
David Williams
Severe Combined Immunodeficiency, X Linked, Gene Therapy
10/26
10/28
NCT02247843: Stem Cell Gene Therapy for Sickle Cell Disease

Active, not recruiting
1/2
4
US
βAS3-FB vector transduced peripheral blood CD34+ cells, Lenti/βAS3-FB
Donald B. Kohn, M.D., California Institute for Regenerative Medicine (CIRM)
Sickle Cell Disease
12/25
12/25
NCT02082353: Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995

Enrolling by invitation
N/A
1480
Canada, US
National Institute of Allergy and Infectious Diseases (NIAID), Rare Diseases Clinical Research Network, Primary Immune Deficiency Treatment Consortium (PIDTC)
Granulomatous Disease, Chronic
11/21
11/21
NCT06282432: Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)

Enrolling by invitation
N/A
9
Europe, US
Rocket Pharmaceuticals Inc.
Leukocyte Adhesion Deficiency
03/37
03/37
Harmatz, Paul
NCT05494593: A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

Recruiting
4
5
US
ELAPRASE, Idursulfase, Rituximab, Methotrexate, Intravenous Immunoglobulin (IVIG)
Takeda, Takeda Development Center Americas, Inc.
Mucopolysaccharidosis (MPS), Hunter Syndrome
07/28
07/28
STARLIGHT, NCT04573023 / 2020-003200-14: A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II

Recruiting
3
80
Europe, US, RoW
JR-141, Idursulfase, JR-141 or Idursulfase
JCR Pharmaceuticals Co., Ltd., JCR Pharmaceuticals Co., Ltd.
Mucopolysaccharidosis II
01/26
01/26
NCT05594992: An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in Mucopolysaccharidosis Type II (Hunter Syndrome) Subjects

Enrolling by invitation
3
80
Europe, US, RoW
JR-141
JCR Pharmaceuticals Co., Ltd.
Mucopolysaccharidosis II
02/28
02/28
NCT03566043: CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)

Active, not recruiting
2/3
48
US, RoW
RGX-121
REGENXBIO Inc.
Mucopolysaccharidosis Type II (MPS II)
11/23
08/25
COMPASS, NCT05371613 / 2021-005200-35: A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) Vs Idursulfase in Pediatric and Young Adult Participants with Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

Recruiting
2/3
54
Europe, Canada, US, RoW
tividenofusp alfa, idursulfase
Denali Therapeutics Inc.
Mucopolysaccharidosis II
12/25
12/25
PROPEL 2, NCT04265651 / 2019-002954-21: Study of Infigratinib in Children with Achondroplasia

Active, not recruiting
2
84
Europe, Canada, US, RoW
Infigratinib 0.016 mg/kg, Infigratinib 0.032 mg/kg, Infigratinib 0.064 mg/kg, Infigratinib 0.128 mg/kg, Infigratinib 0.25 mg/kg
QED Therapeutics, Inc.
Achondroplasia
10/24
12/24
NCT04571970: RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)

Completed
1/2
6
Canada, US
RGX-121
REGENXBIO Inc.
Mucopolysaccharidosis Type II (MPS II)
05/23
05/24
NCT06181136: Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)

Recruiting
1/2
20
US
DNL126
Denali Therapeutics Inc.
Mucopolysaccharidosis Type IIIA
08/28
08/28
NCT04783181: A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)

Active, not recruiting
1/2
8
US
AAV BBP-631
Adrenas Therapeutics Inc
Congenital Adrenal Hyperplasia
02/29
02/29
NCT05845749: Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI

Active, not recruiting
1/2
6
US
Vosoritide Injection [Voxzogo], Vosoritide, BMN111
University of California, San Francisco
MPS IVA, MPS VI
12/25
12/26
NCT04251026 / 2019-004909-27: A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome

Active, not recruiting
1/2
47
Europe, Canada, US
tividenofusp alfa
Denali Therapeutics Inc.
Mucopolysaccharidosis II
07/27
07/27
NCT05682144: ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I

Recruiting
1
2
US
Autologous Plasmablasts (B cells)
Immusoft of CA, Inc.
Mucopolysaccharidosis IH/S, Mucopolysaccharidosis IS
06/25
06/39
NCT05238324: Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II

Withdrawn
1
9
Canada, US
Genetic HMI-203
Homology Medicines, Inc
Mucopolysaccharidosis II
10/24
01/29
NCT06567769: Phase 1 Study of GC1130A in Pediatric Patients with Sanfilippo Syndrome Type a (MPS IIIA)

Recruiting
1
9
US, RoW
GC1130A
GC Biopharma Corp, Novel Pharma Inc.
Sanfilippo Syndrome Type a
06/27
06/27
NCT05795361: Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome

Available
N/A
Europe, US, RoW
Idursulfase-IT, HGT-2310, TAK-609
Takeda
Hunter Syndrome
 
 
NCT04007536: A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome

Completed
N/A
18
Europe, US
No Intervention
Denali Therapeutics Inc.
Mucopolysaccharidosis II
03/24
03/24
PRONTO, NCT05109793: GM1 and GM2 Gangliosidosis PROspective Neurological Disease TrajectOry Study

Active, not recruiting
N/A
31
Europe, US, RoW
Azafaros A.G.
GM1 Gangliosidosis, Sandhoff Disease, Tay-Sachs Disease
05/26
05/26
PROPEL, NCT04035811: Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)

Recruiting
N/A
250
Europe, Canada, US, RoW
QED Therapeutics, Inc.
Achondroplasia
06/26
06/26
NCT04041102: Natural History Study of Infantile and Juvenile GM1 Gangliosidosis (GM1) Patients

Recruiting
N/A
40
Europe, Canada, US, RoW
University of Pennsylvania, Passage Bio, Inc.
GM1 Gangliosidosis
06/26
12/26
Cvijanovich, Natalie Z
SHIPSS, NCT03401398: Stress Hydrocortisone in Pediatric Septic Shock

Recruiting
3
500
Canada, Japan, US, RoW
Hydrocortisone, sodium succinate, SOLU-CORTEF- hydrocortisone sodium succinate injection, Normal saline
Jerry Zimmerman, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Canadian Institutes of Health Research (CIHR), Canadian Critical Care Trials Group, Children's Hospital of Eastern Ontario
Septic Shock
09/26
12/26
GRACE-2, NCT05266001: GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS

Terminated
3
141
US
GM-CSF, Placebo
Nationwide Children's Hospital, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome
12/24
12/24
TRIPS, NCT05267821: Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

Recruiting
2/3
500
US
Anakinra, Placebo
Nationwide Children's Hospital, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
05/27
08/27
ICECAP, NCT05376267: Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-)

Recruiting
N/A
900
Europe, Canada, US, RoW
Therapeutic Hypothermia
University of Michigan, National Heart, Lung, and Blood Institute (NHLBI), Kennedy Krieger Institute, Baltimore, MD
Cardiac Arrest, Out-Of-Hospital, Hypothermia, Induced, Hypoxia-Ischemia, Brain
03/28
03/28
Vichinsky, Elliot P
THRIVE-131, NCT04935879: A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

Completed
3
243
Europe, US, RoW
Inclacumab, Placebo
Pfizer
Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis
06/24
06/24
Perito, Emily
INSPPIRE 2, NCT06651580: Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, Study

Recruiting
N/A
1600
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Chronic Pancreatitis, Exocrine Pancreas Carcinoma, Recurrent Acute Pancreatitis
02/27
02/27
SPaRO, NCT05241847: Starzl Network Patient Reported Outcomes

Active, not recruiting
N/A
202
Canada, US
PeLTQL delivery via electronic means, Real Time Clinic mobile application
University of Pittsburgh, Icahn School of Medicine at Mount Sinai, The Hospital for Sick Children, Emory-Children's Center, Columbia University, Seattle Children's Hospital, University of San Francisco
Liver Transplant; Complications, Quality of Life, Child Behavior, Adolescent Behavior
03/24
07/25
Moriarty, Marci
003SCD101, NCT03653247: A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

Checkmark Initial data from PRECIZN-1 trial for autologous hematopoietic stem cell transplantation in patients with severe sickle cell disease at ASH 2021
Nov 2021 - Nov 2021: Initial data from PRECIZN-1 trial for autologous hematopoietic stem cell transplantation in patients with severe sickle cell disease at ASH 2021
Checkmark Initial data from PRECIZN-1 trial for sickle cell disease
Mar 2021 - Mar 2021: Initial data from PRECIZN-1 trial for sickle cell disease
Active, not recruiting
1/2
8
US
Plerixafor, Busulfan, BIVV003, Autologous CD34 + hematopoietic stem cells
Sangamo Therapeutics
Sickle Cell Disease
07/25
07/25
NCT04774536: Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease

Recruiting
1/2
9
US
CRISPR_SCD001
Mark Walters, MD, University of California, Los Angeles, University of California, Berkeley
Sickle Cell Disease
03/27
03/29
Decaris, Julie
THRIVE-132, NCT04927247: A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

Terminated
3
72
Europe, US, RoW
Inclacumab, Placebo
Pfizer
Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
11/23
11/23
THRIVE-131, NCT04935879: A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

Completed
3
243
Europe, US, RoW
Inclacumab, Placebo
Pfizer
Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis
06/24
06/24
HIBISCUS, NCT04624659 / 2020-003884-25: A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease

Recruiting
2/3
344
Europe, Canada, US, RoW
Etavopivat Tablets Low dose, FT-4202, Etavopivat Tablets High dose, Placebo Tablets, placebo, Etavopivat Tablets
Forma Therapeutics, Inc., Novo Nordisk A/S
Sickle Cell Disease
03/26
04/27
Phan, Huong
NCT03692897: An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

Recruiting
N/A
5000
Canada, US
All approved therapies for the treatment of Chronic Hepatitis B (CHB)
Target PharmaSolutions, Inc.
Hepatitis B, Hepatitis, Liver Diseases
01/26
01/26
Bascon, Cyrus
NCT04774536: Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease

Recruiting
1/2
9
US
CRISPR_SCD001
Mark Walters, MD, University of California, Los Angeles, University of California, Berkeley
Sickle Cell Disease
03/27
03/29
Imagine-1, NCT04713475 / 2020-001109-22: Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis

Active, not recruiting
1/2
26
Europe, Canada, US, RoW
PBGM01
Passage Bio, Inc.
GM1 Gangliosidosis, GM1 Gangliosidosis, Type I, GM1 Gangliosidosis, Type 2, Beta-Galactosidase-1 (GLB1) Deficiency
02/26
02/29
NCT04041102: Natural History Study of Infantile and Juvenile GM1 Gangliosidosis (GM1) Patients

Recruiting
N/A
40
Europe, Canada, US, RoW
University of Pennsylvania, Passage Bio, Inc.
GM1 Gangliosidosis
06/26
12/26
Mahuvakar, Shivani
NCT02852213: A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

Recruiting
1
42
US
AAV2-hAADC, Adeno Virus Human Aromatic L-Amino Acid Decarboxylase
Krzysztof Bankiewicz, National Institute of Neurological Disorders and Stroke (NINDS), University of California, San Francisco
AADC Deficiency
07/27
07/31
STEALTH, NCT05432986: Assessment of CSF Shunt Flow With Thermal Measurements B

Completed
N/A
141
US
Thermal Anisotropy Measurement Device, FlowSense
Rhaeos, Inc.
Hydrocephalus
11/23
11/23
Glomb, Nicolaus
PediDOSE, NCT05121324: Pediatric Dose Optimization for Seizures in Emergency Medical Services

Recruiting
3
6000
US
Standardized seizure protocol, midazolam, Conventional seizure protocol
Stanford University, National Institute of Neurological Disorders and Stroke (NINDS), University of Utah, Baylor College of Medicine
Seizures
07/26
09/26
PSCIRAT, NCT05049330: Development and Testing of a Pediatric Cervical Spine Injury Risk Assessment Tool

Recruiting
N/A
22222
US
Julie Leonard
Cervical Spine Injury
09/24
09/26
Lynch, Leslie
PROPEL 2, NCT04265651 / 2019-002954-21: Study of Infigratinib in Children with Achondroplasia

Active, not recruiting
2
84
Europe, Canada, US, RoW
Infigratinib 0.016 mg/kg, Infigratinib 0.032 mg/kg, Infigratinib 0.064 mg/kg, Infigratinib 0.128 mg/kg, Infigratinib 0.25 mg/kg
QED Therapeutics, Inc.
Achondroplasia
10/24
12/24
NCT05845749: Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI

Active, not recruiting
1/2
6
US
Vosoritide Injection [Voxzogo], Vosoritide, BMN111
University of California, San Francisco
MPS IVA, MPS VI
12/25
12/26
PROPEL, NCT04035811: Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)

Recruiting
N/A
250
Europe, Canada, US, RoW
QED Therapeutics, Inc.
Achondroplasia
06/26
06/26
Alvarado, Alejandra
SPaRO, NCT05241847: Starzl Network Patient Reported Outcomes

Active, not recruiting
N/A
202
Canada, US
PeLTQL delivery via electronic means, Real Time Clinic mobile application
University of Pittsburgh, Icahn School of Medicine at Mount Sinai, The Hospital for Sick Children, Emory-Children's Center, Columbia University, Seattle Children's Hospital, University of San Francisco
Liver Transplant; Complications, Quality of Life, Child Behavior, Adolescent Behavior
03/24
07/25
Kelly, Shannon
NCT05598723: BOTOX® vs. XEOMIN® for Chronic Migraine

Recruiting
3
128
US
IncobotulinumtoxinA (XEOMIN®), Xeomin, OnabotulinumtoxinA (BOTOX®), Botox
Naval Medical Center Camp Lejeune
Chronic Migraine
02/25
08/25
RBC-IMPACT, NCT05255445: Red Blood Cell - IMProving trAnsfusions for Chronically Transfused Recipients

Completed
N/A
157
US, RoW
Red Blood Cell (RBC) Transfusion
Westat, National Heart, Lung, and Blood Institute (NHLBI), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Sickle Cell Disease, Thalassemia, Pediatric Cancer
03/24
03/24
Roth, Danielle
NCT04251026 / 2019-004909-27: A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome

Active, not recruiting
1/2
47
Europe, Canada, US
tividenofusp alfa
Denali Therapeutics Inc.
Mucopolysaccharidosis II
07/27
07/27
NCT04007536: A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome

Completed
N/A
18
Europe, US
No Intervention
Denali Therapeutics Inc.
Mucopolysaccharidosis II
03/24
03/24
Sako, Annie
COMPASS, NCT05371613 / 2021-005200-35: A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) Vs Idursulfase in Pediatric and Young Adult Participants with Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

Recruiting
2/3
54
Europe, Canada, US, RoW
tividenofusp alfa, idursulfase
Denali Therapeutics Inc.
Mucopolysaccharidosis II
12/25
12/25
CANaspire, NCT04998396: A Study of AAV9 Gene Therapy in Participants With Canavan Disease ( Clinical Trial)

Recruiting
1/2
26
US
AAV9 BBP-812
Aspa Therapeutics
Canavan Disease
10/26
10/30
NCT04251026 / 2019-004909-27: A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome

Active, not recruiting
1/2
47
Europe, Canada, US
tividenofusp alfa
Denali Therapeutics Inc.
Mucopolysaccharidosis II
07/27
07/27
Fields, Jenna
NCT05238324: Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II

Withdrawn
1
9
Canada, US
Genetic HMI-203
Homology Medicines, Inc
Mucopolysaccharidosis II
10/24
01/29
NCT06567769: Phase 1 Study of GC1130A in Pediatric Patients with Sanfilippo Syndrome Type a (MPS IIIA)

Recruiting
1
9
US, RoW
GC1130A
GC Biopharma Corp, Novel Pharma Inc.
Sanfilippo Syndrome Type a
06/27
06/27
Elzie-Tuttle, Nicole
NCT04400071: Biology and Benefits of Music Play and Stories for Kids/Parents During ALL Treatment

Recruiting
N/A
250
US
Active Music Engagement, Audio Storybooks
Indiana University, Children's Mercy Hospital Kansas City, Ann & Robert H Lurie Children's Hospital of Chicago, National Institute of Nursing Research (NINR), James Whitcomb Riley Hospital for Children, UCSF Benioff Children's Hospital Oakland
Acute Lymphoblastic Leukemia, Pediatric, Pediatric Cancer
06/25
06/25

Download Options